AstraZeneca ready to go in new phase of global trial on Covid-19 vaccine

AstraZeneca AstraZeneca is likely to build an additional global trial to check the efficiency of its Covid-19 vaccine using a small dosage, its chief executive was quoted as saying on Thursday amid questions over the results from its late-stage study. "Now that we've found what looks like a better efficacy we have to validate this, so we need to do an additional study," he said. Soriot advise it would be another "international study, but this one could be faster because we know the efficacy is high so we need a smaller number of patients." The news comes as AstraZeneca faces questions about its passing that some experts say could create problem of its chances of getting speedy US and EU regulatory approval. Many scientists and researchers have raised doubts about the robustness of results released on Monday showing the experimental vaccine was 90 per cent effective in a sub-group of trial participants who, by error initially, received a half dose followed by ...